A Phase Ib Dose De-escalation Study of the Combination of Tamoxifen Plus Goserelin Acetate With Alpelisib (BYL719) or Buparlisib (BKM120) in Premenopausal Patients With Hormone Receptor-positive/HER2-negative Locally Advanced or Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 03 May 2017
At a glance
- Drugs Alpelisib (Primary) ; Buparlisib (Primary) ; Goserelin; Tamoxifen
- Indications Advanced breast cancer
- Focus Adverse reactions
- Acronyms B-YOND
- Sponsors Novartis
- 27 Apr 2017 Planned End Date changed from 1 Mar 2017 to 31 Dec 2017.
- 27 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 31 Dec 2017.
- 27 Nov 2016 Planned End Date changed from 1 May 2016 to 1 Mar 2017.